NCT02049112已完成4 期
Phase 4 Study Evaluating Efficacy, Safety and Acceptability of Treatment With a New Salivary Equivalent Compared to Two Moisturizing Mouth Sprays on the Improvement of Dry Mouth Symptoms and Oral Comfort in Patients With Xerostomia.
Unither Pharmaceuticals, France2 个研究点 分布在 1 个国家目标入组 210 人开始时间: 2012年1月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 210
- 试验地点
- 2
- 主要终点
- Dry mouth discomfort
研究概览
简要总结
The purpose of this study is to evaluate the clinical efficacy, safety and acceptability of our new oral salivary equivalent in the relief of signs and symptoms related to mouth dryness as compared to two distinct moisturizing currently marketed oral sprays (Aequasyal® & Biotene®) in patients with xerostomia due to chronic hyposalivation.
详细描述
National, multicentre, randomised, active controlled, crossover, open-label study using a 3-latin-square design.
200 evaluable patients have been recruited
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years or more,
- •Clinical diagnosis of xerostomia by a severe reduction of salivation, as detected by patient's answers to few specific questions and measured by saliva volume at screening visit (test of saliva weight absorbed ≤ 0.1g/min)
- •Any medical condition or treatment leading to a severe reduction of salivation related to either:
- •Head and neck radiation therapy for cancer,
- •Gougerot-Sjögren syndrome
- •Medications known to induce xerostomia (psychotropic drugs, antihypertensive drugs)
- •Dehydration, hypothyroidism, Parkinson's disease and/or diabetes mellitus
- •Female patients must be post-menopausal or using a highly effective method for avoidance of pregnancy throughout the whole study duration, if childbearing potential.
- •Able to understand and comply with the protocol procedures
- •Willing and able to give their written informed consent
- •Affiliated to the French National Health Insurance Program
排除标准
- •Known hypersensitivity to one of the study products or to one of their components
- •Any planned change in dosing of all known medications inducing mouth dryness
- •Concomitant treatment for xerostomia symptoms without a scheduled 3 to 7-day withdrawal window
- •Oral candidiasis as diagnosed by a microbiological test obtained from an unstimulated whole saliva sample until 3-week period from disease release
- •Oral ulceration
- •Alcohol (>2 glasses of wine/day), smoking (>10 cigarettes/day), caffeine and/or theine intake (>4 cups/day)
- •Patients unable to fill out the questionnaires or to comply with the study protocol
- •Dental infection
- •Patients participating to another clinical trial at the time of the study entry or within 30 days prior to study enrolment
- •Life-threatening condition at the time of the study
- •Pregnant or lactating women and women of childbearing potential refusing to use adequate contraception.
结局指标
主要结局
Dry mouth discomfort
时间窗: 14 days
Patient evaluation through the completion of a self rated 100 mm long VAS score. Anchor points of the VAS score will be 0 representing the absence of any dry mouth symptoms and 100 representing the worst imaginable picture of dry mouth discomfort
次要结局
- Taste perversion(14 days)
- Medical device acceptability(14 days)
- Medical device safety assessment(14 days)
- Mouth burning sensation(14 days)
- Speech difficulties(14 days)
- Chewing difficulties(14 days)
- Swallowing difficulties(14 days)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
4 期
To compare combination of study with marketed other combination of drug in patients having both anxiety and depression.CTRI/2022/11/047050Mankind Pharma Limited
已完成
4 期
A Post Marketing study of VELSEAL to control the bleeding from severely bleeding wounds due to accidents, trauma cases and deep arterial wounds.CTRI/2018/03/012373Datt Mediproducts Pvt Ltd101
进行中（未招募）
4 期
To assess how safe and effective Visanne (Dienogest) is in managing pelvic pain caused due to endometriosisCTRI/2022/04/041870Bayer Pharmaceuticals Pvt Ltd
已完成
4 期
A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE TerritoriesHIV InfectionsNCT05514509ViiV Healthcare370
已完成
4 期
A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of AgePoliomyelitisNCT02580201Fidec Corporation154